Delivery of physiologically active compounds through an inhalation route
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/12
A61K-009/14
A61M-015/00
출원번호
US-0479509
(2006-06-30)
등록번호
US-7507398
(2009-03-24)
발명자
/ 주소
Rabinowitz,Joshua D
Zaffaroni,Alejandro C
출원인 / 주소
Alexza Pharmaceuticals, Inc.
대리인 / 주소
Swanson & Bratschun, L.L.C.
인용정보
피인용 횟수 :
45인용 특허 :
162
초록▼
The present invention relates to the delivery of physiologically active compounds through an inhalation route. Specifically, it relates to aerosols containing physiologically active compounds that are used in inhalation therapy. In a method aspect of the present invention, the physiologically activ
The present invention relates to the delivery of physiologically active compounds through an inhalation route. Specifically, it relates to aerosols containing physiologically active compounds that are used in inhalation therapy. In a method aspect of the present invention, the physiologically active compound is delivered to a patient through an inhalation route. The method comprises: a) heating a coating of a physiologically active compound, on a solid support, to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% physiologically active compound degradation products. In a kit aspect of the present invention, a kit for delivering a physiologically active compound through an inhalation route is provided which comprises: a) a thin coating of a physiologically active compound, and b) a device for dispensing said thin coating as a condensation aerosol.
대표청구항▼
The invention claimed is: 1. A condensation aerosol for delivery of chlordiazepoxide formed by heating a composition containing chlordiazepoxide coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at
The invention claimed is: 1. A condensation aerosol for delivery of chlordiazepoxide formed by heating a composition containing chlordiazepoxide coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of chlordiazepoxide and less than 5 percent by weight of chlordiazepoxide degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 3. The condensation aerosol according to claim 1 or claim 2, wherein the geometric standard deviation around the MMAD is less than 3.0. 4. A condensation aerosol for delivery of betahistine formed by heating a composition containing betahistine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of betahistine and less than 5 percent by weight of betahistine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 5. The condensation aerosol according to claim 4, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 6. The condensation aerosol according to claim 4 or claim 5, wherein the geometric standard deviation around the MMAD is less than 3.0. 7. A condensation aerosol for delivery of clonidine formed by heating a composition containing clonidine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of clonidine and less than 5 percent by weight of clonidine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 8. The condensation aerosol according to claim 7, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 9. The condensation aerosol according to claim 7 or claim 8, wherein the geometric standard deviation around the MMAD is less than 3.0. 10. A condensation aerosol for delivery of testosterone formed by heating a composition containing testosterone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of testosterone and less than 5 percent by weight of testosterone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 11. The condensation aerosol according to claim 10, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 12. The condensation aerosol according to claim 10 or claim 11, wherein the geometric standard deviation around the MMAD is less than 3.0. 13. A condensation aerosol for delivery of a conjugated estrogen formed by heating a composition containing the conjugated estrogen coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of the conjugated estrogen and less than 5 percent by weight of the conjugated estrogen degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 14. The condensation aerosol according to claim 13, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 15. The condensation aerosol according to claim 13 or claim 14, wherein the geometric standard deviation around the MMAD is less than 3.0. 16. A condensation aerosol for delivery of estradiol formed by heating a composition containing estradiol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of estradiol and less than 5 percent by weight of estradiol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 17. The condensation aerosol according to claim 16, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 18. The condensation aerosol according to claim 16 or claim 17, wherein the geometric standard deviation around the MMAD is less than 3.0. 19. A condensation aerosol for delivery of ethinyl estradiol formed by heating a composition containing ethinyl estradiol coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of ethinyl estradiol and less than 5 percent by weight of ethinyl estradiol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 20. The condensation aerosol according to claim 19, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 21. The condensation aerosol according to claim 19 or claim 20, wherein the geometric standard deviation around the MMAD is less than 3.0. 22. A condensation aerosol for delivery of hyoscyamine formed by heating a composition containing hyoscyamine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of hyoscyamine and less than 5 percent by weight of hyoscyamine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 23. The condensation aerosol according to claim 22, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 24. The condensation aerosol according to claim 22 or claim 23, wherein the geometric standard deviation around the MMAD is less than 3.0. 25. A method of forming a chlordiazepoxide containing aerosol comprising: (a) heating a composition containing chlordiazepoxide coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of chlordiazepoxide degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 26. The method according to claim 25, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 27. The method according to claim 26, wherein the coated composition comprises at least 10 percent by weight of chlordiazepoxide. 28. A method of forming a betahistine containing aerosol comprising: (a) heating a composition containing betahistine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of betahistine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 29. The method according to claim 28, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 30. The method according to claim 29, wherein the coated composition comprises at least 10 percent by weight of betahistine. 31. A method of forming a clonidine containing aerosol comprising: (a) heating a composition containing clonidine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of clonidine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 32. The method according to claim 31, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 33. The method according to claim 32, wherein the coated composition comprises at least 10 percent by weight of clonidine. 34. A method of forming a testosterone containing aerosol comprising: (a) heating a composition containing testosterone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of testosterone degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 35. The method according to claim 34, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 36. The method according to claim 35, wherein the coated composition comprises at least 10 percent by weight of testosterone. 37. A method of forming a conjugated estrogen containing aerosol comprising: (a) heating a composition containing the conjugated estrogen coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of the conjugated estrogen degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 38. The method according to claim 37, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 39. The method according to claim 38, wherein the coated composition comprises at least 10 percent by weight of the conjugated estrogen. 40. A method of forming an estradiol containing aerosol comprising: (a) heating a composition containing estradiol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of estradiol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 41. The method according to claim 40, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 42. The method according to claim 41, wherein the coated composition comprises at least 10 percent by weight of estradiol. 43. A method of forming an ethinyl estradiol containing aerosol comprising: (a) heating a composition containing ethinyl estradiol coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of ethinyl estradiol degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 44. The method according to claim 43, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 45. The method according to claim 44, wherein the coated composition comprises at least 10 percent by weight of ethinyl estradiol. 46. A method of forming a hyoscyamine containing aerosol comprising: (a) heating a composition containing hyoscyamine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of hyoscyamine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 47. The method according to claim 46, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 48. The method according to claim 47, wherein the coated composition comprises at least 10 percent by weight of hyoscyamine. 49. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estradiol, ethinyl estradiol, and hyoscyamine, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 50. The method according to claim 49, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 51. The method according to claim 50, wherein the coated composition comprises at least 10 percent by weight of the drug. 52. A method of forming a drug containing aerosol comprising: (a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estradiol, ethinyl estradiol, and hyoscyamine, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 53. The method according to claim 52, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 54. The method according to claim 53, wherein the coated composition comprises at least 10 percent by weight of the salt form of the drug. 55. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool. 56. The condensation aerosol according to claim 5, wherein the condensing comprises allowing the vapor to cool. 57. The condensation aerosol according to claim 8, wherein the condensing comprises allowing the vapor to cool. 58. The condensation aerosol according to claim 11, wherein the condensing comprises allowing the vapor to cool. 59. The condensation aerosol according to claim 14, wherein the condensing comprises allowing the vapor to cool. 60. The condensation aerosol according to claim 17, wherein the condensing comprises allowing the vapor to cool. 61. The condensation aerosol according to claim 20, wherein the condensing comprises allowing the vapor to cool. 62. The condensation aerosol according to claim 23, wherein the condensing comprises allowing the vapor to cool. 63. The method according to claim 26, wherein the condensing comprises allowing the vapor to cool. 64. The method according to claim 29, wherein the condensing comprises allowing the vapor to cool. 65. The method according to claim 32, wherein the condensing comprises allowing the vapor to cool. 66. The method according to claim 35, wherein the condensing comprises allowing the vapor to cool. 67. The method according to claim 38, wherein the condensing comprises allowing the vapor to cool. 68. The method according to claim 41, wherein the condensing comprises allowing the vapor to cool. 69. The method according to claim 44, wherein the condensing comprises allowing the vapor to cool. 70. The method according to claim 47, wherein the condensing comprises allowing the vapor to cool. 71. The method according to claim 50, wherein the condensing comprises allowing the vapor to cool. 72. The method according to claim 53, wherein the condensing comprises allowing the vapor to cool. 73. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of chlordiazepoxide, betahistine, clonidine, testosterone, conjugated estrogens, estradiol, ethinyl estradiol, and hyoscyamine, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. 74. The method according to claim 73, wherein the condensation aerosol is formed at a rate greater than 1 mg/second. 75. The method according to claim 74, wherein the condensation aerosol is formed at a rate greater than 2 mg/second. 76. The method according to claim 75, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns. 77. The method according to claim 74, wherein the condensing comprises allowing the vapor to cool.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (162)
Sands George H., 5HT 1 receptor agonists and metoclopramide for the treatment of migraine.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Clearman Jack F. (Blakely GA) Chiou Joseph J. (Clemmons NC) Williams Darrell D. (Winston-Salem NC) Casey William J. (Clemmons NC) Gentry Thomas L. (Winston-Salem NC) Squires William C. (Winston-Salem, Aerosol delivery article.
Roberts Donald L. (Winston-Salem NC) Morrison Carl C. (Winston-Salem NC) Brooks Johnny L. (Winston-Salem NC) Crooks Evon L. (Winston-Salem NC) Ingebrethsen Bradley J. (Winston-Salem NC), Aerosol delivery article.
Horvath, Raymond F.; Tran, Jennifer; De Lombaert, Stephane; Hodgetts, Kevin J.; Carpino, Philip A.; Griffith, David A., Certain alkylene diamine-substituted heterocycles.
Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Wensley, Martin J., Delivery of aerosols containing small particles through an inhalation route.
Hale, Ron L.; Rabinowitz, Joshua D.; Solas, Dennis W.; Zaffaroni, Alejandro C., Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route.
Hale,Ron L.; Rabinowitz,Joshua D.; Solas,Dennis W.; Zaffaroni,Alejandro C., Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route.
Hale,Ron L.; Rabinowitz,Joshua D.; Solas,Dennis W.; Zaffaroni,Alejandro C., Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route.
Reed Barry Leonard,AUX ; Morgan Timothy Matthias,AUX ; Finnin Barrie Charles,AUX, Dermal penetration enhancers and drug delivery systems involving same.
Potter Dennis L. (Kernersville NC) Raker Mark L. (Clemmons NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) Westmoreland Amos E. (Winston-Salem NC) Woods Donna K. (W, Drug delivery article.
Brooks Johnny L. (Winston-Salem NC) Roberts Donald L. (Winston-Salem NC) Simmons Jerry S. (Rural Hall NC), Drug delivery articles utilizing electrical energy.
Hodson Peter David (Trowell Park GB3) Smith David Keith (Loughborough GB3) Wass Anthony Charles Lammond (Duddington GB3), Dry powder inhalation device having deagglomeration/aerosolization structure responsive to patient inhalation.
Sprinkel F. Murphy (Glen Allen VA) Das Amitabh (Midlothian VA) Fleischhauer Grier S. (Midlothian VA) Grollimund Everett C. (Midlothian VA) Houck ; Jr. Willie G. (Richmond VA) Lipowicz Peter J. (Midlo, Electrical lighter with a rotatable tobacco supply.
Higgins Charles T. (Richmond VA) Raymond Wynn R. (Chesterfield VA) Sprinkel Francis M. (Glen Allen VA), Electrical smoking article using liquid tobacco flavor medium delivery system.
Brooks Johnny L. (Winston-Salem NC) Roberts Donald L. (Winston-Salem NC) Simmons Jerry S. (Rural Hall NC), Flavor delivery articles utilizing electrical energy.
Counts Mary E. (Richmond VA) LaRoy Bernard C. (Richmond VA) Losee ; Jr. D. Bruce (Richmond VA) Morgan Constance H. (Midlothian VA) Smith Ulysses (Midlothian VA) Sprinkel ; Jr. F. Murphy (Glen Allen V, Flavor generating article.
Counts Mary E. (Richmond VA) Hajaligol Mohammad R. (Richmond VA) Morgan Constance H. (Midlothian VA) Smith Ulysses (Midlothian VA) Sprinkel Francis M. (Glen Allen VA) Utsch Francis V. (Midlothian VA), Flavor-delivery article.
Weers Jeffry G. ; Dellamary Luis A. ; Tarara Thomas E. ; Trevino Leo A. ; Ranney Helen M., Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents.
Rubsamen Reid M. (Berkeley CA) Lloyd Lester J. (Orinda CA) Johansson Eric T. (Dublin CA), Lockout device for controlled release of drug from patient-activated dispenser.
Clearman Jack F. (Blakely GA) Furin Olivia P. (Clemmons NC) Chiou Joseph J. (Clemmons NC) Squires William C. (Winston-Salem NC), Low CO smoking article.
Radhakrishnan Ramachandran (Fremont CA) Mihalko Paul J. (Fremont CA) Abra Robert M. (San Francisco CA), Method and apparatus for administering dehydrated liposomes by inhalation.
Banerjee Chandra K. (Pfafftown NC) Farrier Ernest G. (Winston-Salem NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) Shannon Michael D. (Lewisville NC) Shelar Gary R, Method for making aerosol generating cartridge.
Olsson Sven-Gunnar,SEX ; Rydgren Goran,SEX ; Larsson Anders,SEX ; Niininen Tarmo,SEX, Method for vaporizing an anesthetic liquid and vaporizer operating according to the method.
Banerjee Chandra K. (1 Pfafftown NC) Farrier Ernest G. (1 Winston-Salem NC) Reynolds ; IV John H. (1 Winston-Salem NC) Ridings Henry T. (Lewisville NC) Sensabaugh ; Jr. Andrew J. (Winston-Salem NC) S, Smoking article.
Banerjee Chandra K. (Pfafftown NC) Farrier Ernest G. (Winston-Salem NC) Harris James L. (Westfield NC) Norman Alan B. (Clemmons NC) Resce James L. (Yadkinville NC) Reynolds ; IV John H. (Winston-Sale, Smoking article.
Serrano Mark A. (Greenwich CT) Houghton Kenneth S. (Midlothian VA) Lanzillotti Harry V. (Midlothian VA) Sanders Edward B. (Richmond VA) Lilly ; Jr. A. Clifton (Chesterfield VA) Hayward Charles R. (Mi, Smoking article.
Clearman Jack F. (Blakely GA) Resce James L. (Yadkinville NC) Farrier Ernest G. (Winston-Salem NC) Norman Alan B. (Clemmons NC) Furin Olivia P. (Clemmons NC) Squires William C. (Winston-Salem NC), Smoking article with improved fuel element.
Brooks Johnny L. (Winston-Salem NC) Roberts Donald L. (Winston-Salem NC) Simmons Jerry S. (Rural Hall NC), Smoking articles utilizing electrical energy.
Sutton Andrew D.,GBX ; Johnson Richard A.,GBX ; Senior Peter J.,GBX ; Heath David,GBX, Spray-dried microparticles and their use as therapeutic vehicles.
Lloyd Lester J. (Orinda CA) Lloyd Peter M. (Oakland CA) Rubsamen Reid M. (Berkeley CA) Schuster Jeffrey A. (Berkeley CA), Systems for the intrapulmonary delivery of aerosolized aqueous formulations.
Zanella, John Myers; McKay, William F.; King, Vanja Margareta; Hobot, Christopher M.; Hildebrand, Keith R., Alpha adrenergic receptor agonists for treatment of inflammatory diseases.
Zanella, John Myers; Hobot, Christopher M.; Biggs, Danielle L.; Shaw, Katara; McDonald, Phillip Edward; King, Vanja Margareta; McKay, William F.; Remsen, Kathy L., Clonidine formulations in a biodegradable polymer carrier.
Zanella, John Myers; Hobot, Christopher M.; Biggs, Danielle L.; Shaw, Katara; McDonald, Phillip Edward; King, Vanja Margareta; McKay, William F.; Remsen, Kathy L., Clonidine formulations in a biodegradable polymer carrier.
Zanella, John Myers; Hobot, Christopher M.; Biggs, Danielle L.; Shaw, Katara; McDonald, Phillip Edward; King, Vanja Margareta; McKay, William F.; Remsen, Kathy L., Clonidine formulations in a biodegradable polymer carrier.
McDonald, Phillip E.; Wohabrebbi, Amira; Hobot, Christopher M.; King, Vanja M., Compositions and methods for treating post-operative pain using clonidine and bupivacaine.
McDonald, Phillip E.; Wohabrebbi, Amira; Hobot, Christopher M.; King, Vanja M., Compositions and methods for treating post-operative pain using clonidine and bupivacaine.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Lu, Amy T.; Myers, Daniel J.; Rabinowitz, Joshua D.; Wensley, Martin J.; McKinney, Jeffrey A.; Zaffaroni, Alejandro C., Drug condensation aerosols and kits.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Lu, Amy T.; Myers, Daniel J.; Rabinowitz, Joshua D.; Wensley, Martin J.; McKinney, Jeffrey A.; Zaffaroni, Alejandro C., Drug condensation aerosols and kits.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Song, Soonho; Wensley, Martin J.; Myers, Daniel J.; McKinney, Jeffrey A.; Quintana, Reynaldo J.; Rabinowitz, Joshua D., Method of forming an aerosol for inhalation delivery.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Song, Soonho; Wensley, Martin J.; Myers, Daniel J.; McKinney, Jeffrey A.; Quintana, Reynaldo J.; Rabinowitz, Joshua D., Method of forming an aerosol for inhalation delivery.
Hale, Ron L.; Hodges, Craig C.; Lloyd, Peter M.; Mufson, Daniel; Rogers, Daniel D.; Song, Soonho; Wensley, Martin J.; Myers, Daniel J.; McKinney, Jeffrey A.; Quintana, Reynaldo J.; Rabinowitz, Joshua D., Method of forming an aerosol for inhalation delivery.
McKay, William F.; Wohabrebbi, Amira; King, Vanja Margareta; McDonald, Phillip Edward; Hobot, Christopher M.; Carter, Troy, Methods and compositions for treating post-operative pain comprising clonidine.
McKay, William F.; Wohabrebbi, Amira; King, Vanja Margareta; McDonald, Phillip Edward; Hobot, Christopher M.; Carter, Troy, Methods and compositions for treating post-operative pain comprising clonidine.
McKay, William F.; Wohabrebbi, Amira; King, Vanja Margareta; McDonald, Phillip Edward; Hobot, Christopher M.; Carter, Troy, Methods and compositions for treating post-operative pain comprising clonidine.
Cross, Stephen D.; Herbette, Mathieu; Kelly, Andrew J. G.; Myers, Daniel J.; Shen, William W.; Timmons, Ryan D.; Tom, Curtis; Virgili, Justin M.; Wensley, Martin J., Multiple dose condensation aerosol devices and methods of forming condensation aerosols.
Hale, Ron L.; Lloyd, Peter M.; Lu, Amy; Myers, Daniel J.; Quintana, Reynaldo J.; Rabinowitz, Joshua D.; Solas, Dennis W.; Song, Soonho; Tom, Curtis; Wensley, Martin J., Rapid-heating drug delivery article and method of use.
Hale, Ron L.; Lloyd, Peter M.; Lu, Amy T.; Rabinowitz, Joshua D.; Wensley, Martin J., Respiratory drug condensation aerosols and methods of making and using them.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Kirshnamohan, Self-contained heating unit and drug-supply unit employing same.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Krishnamohan, Self-contained heating unit and drug-supply unit employing same.
Damani, Ramesh; Hale, Ron L.; Myers, Daniel J.; Quintana, Reynaldo J.; Solas, Dennis W.; Song, Soonho; Soni, Pravin; Tom, Curtis; Sharma, Krishnamohan, Self-contained heating unit and drug-supply unit employing same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.